Skip to Main Content

Amid intense interest in Gilead Sciences (GILD) thanks to its experimental Covid-19 drug, an out-of-left-field report emerged over the weekend that AstraZeneca (AZN) may want to buy or merge with the company.

Although AstraZeneca quickly downplayed the likelihood of any deal, Gilead stock gained, while AstraZeneca shares fell slightly. Naturally, this also triggered speculation among Wall Street analysts about the merits of such a transaction, which would be the largest in pharmaceutical industry history.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!